Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Kaskey's Hierarchy of Needs for Medical Affairs with guest Stephen Dodge, SVP of Medical Affairs for Madrigal Pharmaceuticals

Apr 9, 202438 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Kaskey's Hierarchy of Needs in Medical Affairs: Steering towards Successful Product Launches This episode of Pharma Sessions delves into the evolving role of Medical Affairs in pharmaceutical launches, emphasizing its transition from a supportive to a strategic partnership position. Stephen Dodge, SVP of Medical Affairs at Madrigal Pharmaceuticals has launched 25 products, and shares insights into the crucial involvement of Medical Affairs in launch strategies. The discussion t... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_01I've done uh twenty-five launches, so a lot of them. It's moved from medical affairs being a handy support function for a launch to being a very important strategic partner in the whole launch planning process. In my current role, medical, in a way, co-owns what the launch strategy is because we're a really important part of it.

SPEAKER_00Hello, hello, and welcome to Pharma Sessions, where medical affairs professionals come to learn from each other. Two weeks ago, I was at the MAPS. That's the Medical Affairs Professional Society annual meeting in Puerto Rico. If you aren't aware of this group, definitely search them out as they put on some of the best, most interesting, and most interactive conferences. Might as well have been titled The Artificial Intelligence Medical Affairs Conferences. Everyone was talking about the current state and the future impact of AI and how it's going to be applied to MedAffairs.

SPEAKER_00So that brings us to today's episode. My guest is Stephen Dodge, the SVP of Global Medical Affairs at Magical Pharmaceuticals. We explored an interesting concept. What is the hierarchy of needs for medical affairs? Most people are familiar with Maslow's Hierarchy of Needs, a framework used in motivational psychology, often presented as a pyramid. At the base are physiological needs followed by safety, love belonging, esteem, and self-actualization. The idea being that lower level needs such as food and water and safety must be met before higher level needs can be pursued.

SPEAKER_00So the question we discuss today at length is what does this hierarchy look like for medical affairs, particularly around a launch? Not surprisingly, there's a lot of focus at industry events on things at the top of the pyramid, including new technologies, including artificial intelligence. But I believe the game is largely won or lost before you even get to that point. So let's jump in.

SPEAKER_01I work in the pharmaceutical industry, have for about 22 years. I've worked for big pharma and little pharma, always in medical affairs. It's where I started back in early 2001, at a time when medical affairs was probably still an evolving space, for sure, field medical. I'm a pharmacist by training. Did clinical work for a number of years, and then was approached by Novartis at the time to come aboard in what they had, a very fledgling field medical team.

SPEAKER_01And the reason they were interested in me is I had done a lot of work with payers and organized providers. And so they wanted to get some people aboard who had background in that space, who understood what it was like for a medical group to take on pharmacy risk, for example. So they pulled me aboard, and then I just started a journey where I worked in the field in California and then led a team in the Midwest, and then moved into headquarters at Novartis all in a relatively short period of time, and then was leading a couple different national teams, did a few other headquarters jobs, and then moved through some other companies, moved over to Novonordisk and then to Merck, and then moved into small, much smaller farm.

SPEAKER_01I went to Intercept and I'm now at a really small company.

SPEAKER_00Interesting, interesting. So I'm just curious what medical affairs was like 20 years ago. Had you heard of this as an organization? You probably knew of field teams, and you knew there were people out there seeing doctors, but were you aware of medical affairs?

SPEAKER_01I spent my days before coming into industry engaging with account management people from pharma, and occasionally they would bring in somebody that wore a title or carried a title that included something about medical affairs. They were often pharmacists, sometimes physicians, sometimes other scientific professionals. So I was aware, and I had definitely met with some individuals from different companies, but I didn't really have much insight into what they did other than the True Field medical people.

SPEAKER_01And even those, I wasn't totally clear on what all of them did because they show up differently. So yeah, I would say vaguely aware. I had no concept of the broader medical affairs group and structure that you find in headquarters at companies, doing pubs planning and med-ed, things like that, H E O R. I had limited uh awareness that there was actually a structure called medical affairs, and it's quite big usually in many companies, and today much bigger even than it was back then.

SPEAKER_00Yeah, I was gonna say I've only been working with medical affairs groups for probably seven or eight years, but even in that time, it feels like there's so much of that stuff that you mentioned is now rolling up into medical affairs, like Access Might or HOR, and even five, seven years ago, that might not have been the case. But it's actually an interesting segue into what we're talking about today, which is preparing for a launch, right? Because in order to have a successful launch, I guess two ways of looking at it a lot of things need to go right, or there's a lot of ways it could go wrong.

SPEAKER_00So having all those groups funnel into up through medical affairs, I think makes a lot of sense. But how much of your kind of MetAffairs career has been focused around launch products?

SPEAKER_01What's interesting, and I I think this is from the very get-go, when I came into industry, I think companies were just then realizing that in addition to having kind of a headquarters people doing medical information, that was a classic medical affairs function. Um, some cross-functional support on brand teams and things like that. That there was a realization that if you have people in the field as an example engaging with thought leaders, and then a little bit later, some real strong realization that's also helpful if you have them engaging with payers and others, that becomes an integral part of a launch.

SPEAKER_01And in fact, I would argue today that and anybody in any company would say that if you don't have that, you will not have as successful a launch as you would with that. And so it's a critical part. But when I joined, and then throughout the time I've joined, I've been in, one of the big triggers for building out medical affairs or augmenting it and really getting it large in some cases is the launch or launches. And so when I joined Novartis, it was they were building out a team because we were getting ready to launch some key products, and they hadn't they had no medical affairs support at all for those.

SPEAKER_01I've done 25 launches, so a lot of them. And various responsibilities in those launches from just being an MSL and doing scientific exchange to being the key leader of the medical affairs function is as it relates to the launch. And I think it's moved from medical affairs being a handy support function for a launch to being a very important strategic partner in the whole launch planning process, thinking through what that launch strategy should look like in my current role.

SPEAKER_01Medical, in a way, co-owns what the launch strategy is because we're a really important part of it.

SPEAKER_00Yeah. So the framework that I was interested in thinking about this is this idea of the Maslow's hierarchy of needs, but for medical affairs, right? Because there are there's so much that can there's so much detail, and you can get further and further into it, everything from evidence generation to publication planning, scientific communication, med-ed, KOL engagement, and it just goes on and on. So in the traditional or the most established Maslow's hierarchy of needs, there's about five different five different categories, right?

SPEAKER_00Where you start with your physiological at the bottom, that once that's taken care of, you can move on to safety safety, to love and belonging, to esteem, and then self-actualization, right? This idea where we all want to be the most fulfilled versions of ourself. But you can't do, you can't, the idea is you can't do the top before you have built the foundation for the bottom, right? And I think most people are familiar with that. Right. So from your perspective, what are what's the fundamental pillars, that bottom layer of the Metaphair's hierarchy of needs?

SPEAKER_01Yeah, it's a it's a fun way to think about it. And honestly, I haven't thought about it exactly that way before, but it there's, I think, some relatively obvious foundational things. So, first of all, you decide as an organization which parts of the key functions that need to be part of the company sit in medical affairs. That's interesting, often because in some companies HEOR does or does not, in some companies, publications does or does not, pharmacovigilance might or might not.

SPEAKER_01So you have to make that decision. It's a fundamental decision because what it then allows you to do is say, all right, we're gonna need people that can do these roles. And so for me, foundationally, decide what it is that's gonna sit in the space called medical affairs, um, and then understand based on that what are the critical capabilities you need, and therefore, what kind of people do you need? How do you recruit the people you need so that you have not just the numbers of people, but the skill sets you need and the mindset that you need to do that?

SPEAKER_01That's foundational. And I I have found that the getting good people who really know what they're doing and understand what their responsibilities are, not only is it foundational, it can be done wrong. It can be done in a thoughtless manner. I think then clearly, as you bring people aboard, they help you flesh out, all right, within this space, within the remit of health economics and outcomes research broadly defined, what is it we're gonna do and how are we gonna do it? Because it's been my experience that one person, and a lot little companies do this often, they'll hire a head of medical affairs and then say, figure it all out, right?

SPEAKER_01But they hold the purse strings pretty tightly to say for a long time it's figure it out by yourself. And there's a period where you can do that, but it becomes obvious pretty quickly. You need to start bringing in people who have the experience and expertise, but also have just the bandwidth to think more deeply about their work. So that's it. I think it's I think foundationally it's that. So it and then build around that is a bit of all right, what's the process we're gonna use? And I you can overprocess things, but what I found in small companies is usually the flip side in that is you underprocess.

SPEAKER_01And so you have no process. And so you build out some process so that things get done more efficiently and consistently.

SPEAKER_00So that's really interesting because I was not expecting you to go to the organizational kind of structure and alignment as foundational, because I think some of the assumption is that's defined. But what's really interesting, and as they're saying it, it makes a lot of sense, there is a lot of variance company to company, or maybe even launch to launch. So that's really fascinating. And one of the things you said is you've seen it done wrong, the hiring and the structuring of things. What does it look like when it's done right, in your opinion?

SPEAKER_01I I'll I'll answer it from the perspective of a small company's first launch, because I think that's a really interesting and different kind of way to think about it. And so you're starting almost with a blank sheet of paper off. And that's good news and bad news. Um, because there's almost always a timeline that doesn't change that much, and yet you have to build things and you have to think about them in the context of be sparing about where you spend and and how you bring people on. Um, but I think when it's done, bring in the minimum number of people you need with the skill set and the mindset to get the work done without cutting it so tightly that you burn people out.

SPEAKER_00Right.

SPEAKER_01And that's a real wrestling match with little companies because you don't want to spend more than you need. There's a long period of time where the whole thing is at risk. And that is you get negative data, we all go find new jobs. You're trying to attract really good people, but there's a pretty high risk, and you don't want to burn them out. And so I think that done right, you get enough of the right people that can do the work, that have lots of connections, that know how they can leverage contractors and vendors and things like that, and have those relationships to be able to do that.

SPEAKER_01They have to both be good strategic thinkers because these are big things you're talking about. They have implications over time for the company, but they also have to be able to get the work done too. And so I think that's a that's it's obvious and yet it's not that easy to do. And that is you've got to get really good thinkers who are also doers, and they have to have enough experience to have to be able to think big picture and think about the moving parts that are around them, that if you bring in a less experienced person, they may go, I I know how to do my job, but I'm not really thinking about the broader implications.

SPEAKER_01But you can do that with a very small core group of people. You can have a medical affairs team that's five, eight people and get a lot done, a lot more than you can with two or three. And it's not just the multiplier of it's more people, it's you get better expertise in there. And then build out a phase for how you build the rest of the team out, and then you just work through that as milestones come along that allow you to say, okay, we can take on more risk. So that's generally what I would say.

SPEAKER_00This episode is sponsored by Structured Meetings. It's a Teams app that turns your own teams incidents into the perfect advisory board platform to save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. Interesting. Okay, so once you have your responsibilities defined, your org structure in line, you found those rare kind of player coaches that are that's it's that everybody's looking for, but it's really a difficult thing to manage.

SPEAKER_00But let's say you have that in place and you've agreed on processes, what's the next level of our pyramid here?

SPEAKER_01So it might it it's probably in that space, actually, and it might be part of the foundation, and that is in addition to what, for instance, I think medical affairs would do at a company as you get ready to launch and then go through the launch, there's other stakeholders. So, what is what do you members of clinical development think about that? What is your nascent but growing marketing and a broadly commercial organization think about that? So I do think part of it is carving out with them a really aligned vision for what medical affairs is too.

SPEAKER_01And I but once you do that and you get some people aboard, I do think you put together a medical plan and you say these are some key things we have to do. And again, some of it's very tactical. There's certain things you just have to get done today. Like what? You got to start identifying the thought leaders that are out there, who's really influencing the space, who is it that you need to talk to? And you can start really high on the thought leader pyramid initially. You don't have to say, I've got to figure out who every thought leader is, but who are the key players? If you don't have relationships with them, build those.

SPEAKER_01And that's not just a field medical remit, that is an organizational remit. Really get to know who those people are. Some of them will be involved in your clinical development program, but some of them might not be. So you ask the question, should they be? Should they be in, would it be appropriate for them to be investigators or not? But if not, how are you using them as advisors? What are you hearing from them? How are they thinking? So I think that's important. I think the lifeblood of your company, of any company that's doing uh clinical development and trying to bring a product to market, is your output from your clinical trials.

SPEAKER_01So the studies themselves, and often medical affairs early on, gets involved in just helping with study execution, especially in little companies where they tend to outsource to a CRO the clinical management or the study management. But the minute you get a field medical team, there will be an ask, and it's probably a good ask, or an offer, even if you're not asked, to let those medic those field medical people become a face with those investigators for your company to help both with the trial execution, but just to get to know these people, because some of them are gonna be thought leaders.

SPEAKER_01But you have to have a publication plan, and you have to say, how are we gonna then start to efficiently stream both the information we're generating and a plan around what else we need to generate? So maybe beyond a pub plan, it's an evidence and pub plan. And clinical development tends to think very narrowly about this, and it's the clinical trial. But there's a whole value evidence body of work that needs to be done. And frankly, especially if you're in a disease area that's not really well developed, you may be doing a lot of work that's pure epidemiology, natural history, things like that.

SPEAKER_01Real basic stuff that you're working in diabetes, a lot of that's already established, but not necessarily in another disease. So and medical affairs may be the only group that thinks about that at that point in time. Others will start to realize you don't have it as you get closer to launch, and then it's really hard to make up that time. So I think that kind of a evidence generation and pub strategy is really important next level. You've got people there, they're thinking about that's one of the things they need to be thinking about. So, thought leaders, who are they? Engage them, get to know them, understand what they're thinking, bring insights in as you start to develop your strategy, gut check it with them and bring back here's where it's resonating, here's where it's not.

SPEAKER_01You've got to really have a good value evidence and then evidence dissemination plan as another key piece of that. Um, and you can go a long way with just that small field team out there having conversations with thought leaders, and a good headquarters team thinking both about evidence generation, value evidence broadly, but but otherwise, and then a good publication process to start the stream of your information, both HEOR type information, but also your clinical information.

SPEAKER_01So I would say that's a next key layer, if you will. And it's pretty you can do that fairly small. You don't need a lot of people. The HOR stuff, in fact, my experience has been you can do that heavily through vendors, heavily. But you need somebody who's thinking about it. You can have one person, but you need one person, I believe, who's really thinking about that and they know what they're doing. Yeah.

SPEAKER_00So it's interesting. So it's almost the medical plan and some of this around the pub planning, it's almost uh when you start to get into the translational element of Metafairs, of translating from clinical to the other groups and preparing for preparing to engage with in those KOLs in a way that they're gonna think is interesting or exciting. And likewise with your HUR, your Access people, so that scientific narrative almost building out your the the narrative as well as your plan.

SPEAKER_00And then I would think that kind of the level above that then is then you then the execution of the plan, which in which involves actually doing the publications, involves creating that feedback loop of insights gathering back into the scientific narrative, right? And trick some level of training, I'm assuming, for the or training cadence for the MSLs as the clinical work can continues. So even in in thinking about this, it's almost like it's a pyramid, but there are arrows going backwards as well, where new information is going up and down all the time.

SPEAKER_01Yeah, and I I think so. I think things that kind of get missed often in that build is a really good training plan. And how are you gonna because you hire people, and if you're lucky, you hire all great people, but there's still things you're gonna want them to know that they don't walk through the door knowing, or they don't know the way you want them to know it. So you have to get you have to be good at onboarding. And by the way, most companies, especially early on, big companies, they tend to have this down pretty well, but little companies, they haven't onboarded very many people, period.

SPEAKER_01So a lot of just basic infrastructure is often not there for that to be a good experience. It's been my experience now twice that medical often, because they after the Clint Dev group, the next group that gets built out in a big way starts to be medical, you start testing the capacity of the company to do just basic hiring and onboarding and stuff like that. So there's a fair amount of work you do there that ends up then paying dividends more broadly in the organization as other parts of the organization start to get big quickly.

SPEAKER_01But medical can be a starting point. We basically, at one of the companies I was at, we had to build the whole onboarding process ourselves. But it was a general employee onboarding plus medical onboarding, including training and things like that. I think that the other thing that I have found, and it fits in the hierarchy, but it becomes more of a broader organizational one, and that is at some point, and it's around the time, it could be two years out from launch, it could be, it depends, depends on the situation.

SPEAKER_01You start to get some commercial people and who start thinking about the brand. But their initial eyes and ears around, all right, here's how we're thinking about it. We know what our own science is telling us, but what's the marketplace telling us? Medical becomes a really key part of that because you they may be the only group that's out there actually talking with customers. And that feedback loop, that insight loop becomes really important. And frankly, being able to get a general sense of some key questions and answers that can be provided to the marketing team or the current growing commercial team is really helpful.

SPEAKER_01And what I have found is very quickly as those people come aboard and they start to build out what is a broader marketing capability, a market access capability, etc., they ask medical a lot of questions early on. It's even better if medical is prepared to serve up those answers and just say, hey, I know. You're going to ask this. Let me tell you what we've learned. Which means you have to have been doing the work, thinking about that, and saying we're going to be asking some questions. Nobody in headquarters is telling us yet to ask these questions because they're not even there to ask them, or they're still early in. But these are things we should logically be understanding if we're talking to thought leaders.

SPEAKER_01Are there guidelines out there that they are aware of that make sense that are being used? How are payers thinking about this to the extent that you're having any payer conversations, all of that? And the more of that you've got some field team people and headquarters people saying, be good if we knew some of these answers even early on, and they're often a little bit anecdotal, it will help as the commercial function gets up to up and running broadly, be able to say, here's what we're hearing, and then have a machine in place, if you will, to rapidly iterate on that.

SPEAKER_01So then, okay, we've got three more questions. There's some other things that our commercial colleagues would like to know, or that our clinical development colleagues would like to know. Do we now have a way to quickly get some answers to those? You know, you start doing ad boards and things like that, that might get you some of that. But long before you ever do an ad board, you can just simply say, I'm gonna go talk to thought leaders and see what they say.

SPEAKER_00Because I think the fear that a lot of companies have, that's probably true, is that some MSL in Seattle has a really interesting, could be pivotal conversation, and then maybe that gets logged in this in Viva or whatever, but then nothing happens to that information or it doesn't make it to the person who would have said, Oh my god, this is I thank you so much. This is really amazing. So even yeah, with for I feel like ad boards are almost easier because it's a defined event, and there's probably processes to at least somewhat disseminate the takeaways from that, but it's more the day-to-day work of being on the front lines and engaging people where I think it's likely that stuff is often lost or siloed away.

SPEAKER_00Have you ever seen have you seen people successfully addressing that or creating processes to try to make sure that all of that information flows in a certain way?

SPEAKER_01Yeah, it's uh I have. I've also seen it more often than not done less well than it could. So what you want to be able to do is take in all the information that you're hearing, in some cases, very specifically listening for certain things or even proactively asking for about that, those topics. There's an aspect of getting people out there, but also saying, here's some key things we want you to be listening for or asking about. And by the way, you're gonna hear things we didn't anticipate. So the eyes and ears part's important.

SPEAKER_01Generally, once you get a field team and others who are engaging with customers, as long as they're clear on what it is that's important to the company, they will listen for it and they'll ask about it. Um, but you have to get that process in place. Say, what is it and how do we make sure that we're, whether it's medical leadership, it's marketing, or whomever, is saying this is something we'd really like to understand better, go listen for it or go ask about it, depending on what it is. That piece has to be in place. I've seen that done pretty well, where you have the cross-functional, it can be at the brand team level, it can be in a variety of places, but one topic you always talk about is we have this ability to go learn quickly.

SPEAKER_01Are there any things we want to know? The second piece is the harder piece, in my opinion, and I haven't seen it done as well, and that is to get the information in and interpret it because you're not you're mostly not getting insights, you're just getting data points, and in there, buried in all of that, are the things you go, oh, that's actually something we could action, it's something that's important, etc. That part's much harder to do. I've seen it done fairly well at a couple companies, and one in particular, because we purposely said, not only are we going to go out and try to learn this stuff, we're gonna figure out how to bring it in, interpret it, and then importantly, in a very time-efficient way, get it to the right parts of the organization.

SPEAKER_01You literally need people who that's what they're focused on, and they they manage that process. There's technology out there that is interesting that can help with that. AI is gonna be really fascinating over time to see how much it can be used to take unstructured text, for example, just free text insights, if you will, or learnings, and bringing those together and saying this is something that's resonating out of here that we really need to understand better. I don't think it's quite there yet to do that, but it's fascinating.

SPEAKER_01But you can do it relatively manually. What I have found is if short of any technology, if the team, let's say a field team, knows some of the things that we're really interested in learning quickly, you get them together after they've had some interactions with their thought leaders, and you say, just give me your general gestalt. What is it you learned? Not try to make it as non-aneecdotal as possible. And often they'll do that. Humans will synthesize information relatively well. You can do that to a point. Once you've got thousands and thousands of lines of data, you really need a machine to interpret it.

SPEAKER_01And I'm not sure we're quite there. But so I've seen it done well, and I've seen it done fairly simply. It's got to be iterative. You have, I think the most important part is to do something to report what you're hearing and then let the organization tell you where it needs to be refined. Could it be more specific? Are the reports coming timely enough? Is it even in the right format? How do you have a discussion if a discussion is more useful than a slide or something like that?

SPEAKER_00Right. So I'm almost thinking that this is as we've almost reached the top of our pyramid here. We're in self-actualization, right? Where what we're talking about is the stuff that could potentially be the most most exciting, right? And that's we're doing this iterat if it we're optimizing in stages repeatedly over time, because I can't pronounce that word this morning fairly. And but we've also created this in interrogative mindset, this communicative mindset, right, that flows through the organization. And then there are various tools that might be helpful.

SPEAKER_00But along those same lines, one of the things I've seen companies starting to just uh invest in would be things that are approaching omni-channel type communications or just uh helping your MSLs so that when they go and they're preparing for a meeting, they it's not just the doctor and what they may or may not be prescribing, but it's Dr. Smith tends to see a lot of Medicare patients, so access is a huge issue for them versus Dr. Jones has a kind of a different set of patients and different concerns, and this is what they've responded to in the past.

SPEAKER_00So almost that idea of there's all sorts of activities out there, and I know a lot of pharma companies are trying to tie everything together and do it in a way that's going to ideally direct their people to behave a little bit differently. So it seems like that top layer is once we have everything else and we've got our pubs flowing and we know the scientific narrative and we're tied into commercial, it's then how do we do everything to the best possible way using all the tools that may or may not be available?

SPEAKER_01Yeah, I guess I agree. I guess what I would add is there is a point, and I think it's in every launch for sure, but it's particularly noticeable when it's the first launch in a company that hasn't launched before. And that point is where you realize you have all the pieces in place and you're doing all the work. And to me, that's that moment of real kind of self-actualization, and that's probably in a launch space. Ideally, that's in that period of time, probably about a year before launch.

SPEAKER_01You have phase two data, or you're about to, you probably have it. You haven't filed yet, or you're about to file, but you have all your data. You have your value evidence data, or pretty close to that. You've now got people who are engaging with payer decision makers. You have people you understand what the thought leader universe looks like, and you've got relationships with them, and you're now gonna work really hard to get those as tight as you can before the launch. But you've got a great pubs plan and you're executing it, and that's both manuscripts and it's what you're doing at Congress is you have a good Congress presence and you start to have a company that gets recognized as an actual company, which by the way, that's often started with medical.

SPEAKER_01Your first presence at these big congresses may be exclusively a medical affairs presence or a Clin Dev Medical Affairs Presence. Um, you have the starting of a med-ed program, you're supporting medical education grants, and so that you're also getting third parties out there doing education, you are thinking about who are the advisors you're going to work with for ad boards. You start to build really good content. So not only are you training people for whatever work they're doing, you're starting to build content that's being used at the interface with customers, whether it's scientific exchange with thought leaders, it's talking with payers and doing pre-approval information exchange and starting to do that work with them.

SPEAKER_01And the presence then and identity of medical affairs externally becomes really pronounced, as does the presence and identity internally. And what I have found, and I think it's the point where you go, this is we've got this in place, is you're in all the forums internally where the decisions are being made. In my current case, I have the benefit of I report directly into the CEO, so I don't report into clinical development, nor do I report in a commercial. So medical affairs is truly the third leg of the stool, if you will.

SPEAKER_01And the thinking is medical affairs has to work with both of those functions. It's better if it doesn't sit within either one. You can make it work any way you want. And I've seen the structure work every way, but I think it's a great way to do it. And I think that's where not just me personally, but I think as a team, we get self-actualization. The last thing I'll say is there's a point where you you, and I'm at this point right now, where you know you pull your team together and have a conversation.

SPEAKER_01The team is no longer three or four people, it's whatever it is, depending on the launch, but you have a complete team of people and you have all the perspectives in the room for all the work that needs to be done or is being done, and you sit down and you go, We got a team of people that can get this work done. We have the capabilities in place, and we are doing the work um in real time and executing a good medical launch plan, which that's a fun point to be at. Now, the launch happens or it doesn't happen, and when it happens, it happens well or not.

SPEAKER_01But if the launch happens, that medical has an accountability for and is a real part of strategic partner in that launch is pretty cool. And that didn't used to be the case. It was a supporting function important in a launch, but not the main or not a main player in the launch. I don't, I think that's changed dramatically over the last 20 years.

SPEAKER_00It must be such an amazing feeling, right? Because everything we talked about today is a lot, it's a lot of work. And as you alluded to earlier, there's risk, particularly if you're going to a small company where this is this might be their first launch. But the reason people do that is because there can also be it can be personally very fulfilling, it can be financially rewarding. There's all sorts of good things that can happen when it's done well, done well. So it almost reminds me of being on a sports team or something, and you prepare as much as you can for the game, and then you might win the game, you might lose the game, but if you go into it and you're like, we've done what we were trying, we had a plan, we executed the plan, we're at the point we need to be.

SPEAKER_00I feel like you you really can't ask for much more than that, right? The the outcome will be what it is, but you can only control your own your own strategies and your own efforts. So it it even hearing the way your voice sounds as you're describing, getting to that point, it just sounds very fulfilling in all sorts of ways.

SPEAKER_01Yeah, it's fun. I I also think, and this is probably true, launching any kind of product into any environment, you pull a plan together and and you bring the product to the market, and it's always a big deal. I think it's uniquely a big deal when you're talking about a medication where there's especially if there's significant unmet need, and that is if the plan's executed well, the right patients get your treatment, the wrong patients don't get your treatment, HCPs understand how to use the treatment, payers understand the value proposition and why it makes sense to pay for it, et cetera.

SPEAKER_01But there's a all those pieces have to come together. I think a launch of a medication is probably the most complicated or complex product type launch there is. Launching a new PlayStation, not that it's trivial, I and I've never launched one, but it's way different. And I just think that it's fun. And one of the things I've seen in my career is that medical affairs role in that really complex, very important process that's hopefully bringing a medication to a patient that otherwise wouldn't have it.

SPEAKER_01And by having it, they benefit. They live longer, they live healthier, what have you. It's really a neat thing to be part of that. And I really enjoy the fact that medical's role in that has become much more pronounced than it was even a few years ago, a handful of years ago. It's a we're an integral part of a successful launch, and we get to carry the science, and we get to talk about that science early on and understand it and help shape how the organization thinks about the science, even your own organization.

SPEAKER_01It's really an interesting role. Wonderful.

SPEAKER_00That seems like a great place to leave it for today. So, Stephen, thank you so much.

SPEAKER_01Yeah, my pleasure. It was great to have the chance to have the chat. Thank you.

SPEAKER_00This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side so I can humbly claim some expertise. One of the questions I used to get all the time was, Can we just do this in teams? And the answer back then was not really. Structured meetings changed that by creating an MS Teams app that lets you have these discussions in a really smart way in your own team's instance.

SPEAKER_00It changes teams and just enough to check all the boxes for what is needed for great ad boards. And also it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, we'll go back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode